
AVAILABLE IN A 300 mg PRE‑FILLED PEN
OR 300 mg PRE‑FILLED SYRINGE FOR SUBCUTANEOUS INJECTION
ADULTS
18+ YEARS
Initial loading dose:
600 mg 2 x 300 mg
Followed by:
300 mg Q2W 1 x 300 mg
Get the full dosing regimen
Email Dosing Regimen
PRINT DOSING REGIMEN
For supplemental injection training, visit our Patient Video Injection Support page
Q2W, once every 2 weeks.
Consider before injecting
DUPIXENT is an injectable medicine that is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider.1
- A patient may self-inject DUPIXENT—or a caregiver may administer DUPIXENT—after training has been provided by a healthcare provider on proper subcutaneous injection technique using the pre-filled syringe or pre-filled pen
- It is important to provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use
- After administration, advise patients to follow sharps disposal recommendations
- Patients and/or caregivers should read the Instructions for Use (300 mg pre-filled pen or pre-filled syringe) prior to injecting
- Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT1
At-home or in-office
administration options
Important administration
instructions1
instructions1
Preparation and administration of DUPIXENT
- Patients and/or caregivers should read the Instructions for Use prior to injecting
- Instruct patients and/or caregivers to administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
- The upper arm can also be used if a caregiver administers the injection
- It is important to rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred
- For the initial dose, patients and/or caregivers should administer each DUPIXENT injection at a different injection site
See the Instructions for Use for more detailed instructions on the preparation and administration of DUPIXENT
For supplemental injection training, visit our Patient Video Injection Support page
For supplemental injection training,
visit our Patient Video Injection Support Page
Pre-Filled Pen
Instructions for Use - 300 mgPre-Filled Syringe
Instructions for Use - 300 mg
Additional dosage information
Before injection, instruct patients and/or caregivers to remove DUPIXENT from the refrigerator and allow DUPIXENT to reach room temperature without removing the needle cap.
- 45 minutes for 300 mg/2 mL
Patients and/or caregivers should inspect DUPIXENT for particulate matter and discoloration prior to administration.
Do not use if the liquid contains visible particulate matter or is discolored or cloudy (other than clear to slightly opalescent, colorless to pale yellow).
Patients and/or caregivers should discard any unused product remaining in the pre-filled syringe or pre-filled pen in accordance with local requirements.
For supplemental injection training, visit our Patient Video Injection Support Center
DUPIXENT is a clear to slightly opalescent, colorless to pale yellow solution available as:
- Injection: 300 mg/2 mL in a single-dose, pre-filled pen with hidden needle or syringe with needle shield
DUPIXENT is available in cartons containing 2 pre-filled pens or syringes with needle shields. Each 300 mg pre-filled syringe or pre-filled pen delivers 300 mg/2 mL.
- DUPIXENT is sterile and preservative-free. Patients and/or caregivers should discard any unused portion
- Patients and/or caregivers should store DUPIXENT by refrigerating at 36 °F to 46 °F (2 °C to 8 °C) in the original carton to protect from light
- If necessary, DUPIXENT may be kept at room temperature up to 77 °F (25 °C) for a maximum of 14 days. DUPIXENT should not be stored above 77 °F (25 °C). After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded
- DUPIXENT should not be exposed to heat or direct sunlight
- Do NOT freeze. Do NOT shake
- Any unused medicinal product or waste material should be disposed of in accordance with local requirements
DUPIXENT MyWay®
Get patient access support and information about benefits
investigations, prior authorizations, and medical necessity
and appeal letters.